Latest News and Press Releases
Want to stay updated on the latest news?
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
-
Reference is made to the private placement (the "Private Placement") and the retail offering through PrimaryBid announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR-form related...
-
Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new...
-
Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today...
-
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the...
-
Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and...
-
Oslo, Norway, 17 November, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new...
-
Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering. The...
-
In accordance with the Norwegian Securities Trading Act Section 4-3, Inven2 AS ( “Inven2” ) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 10% threshold...
-
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the...